Immunoglobulin - ProMetic Life Sciences

Drug Profile

Immunoglobulin - ProMetic Life Sciences

Alternative Names: IVIG - ProMetic Life Sciences

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator NantPharma; ProMetic Life Sciences
  • Class Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Immunodeficiency disorders

Most Recent Events

  • 09 Aug 2016 ProMetic announces intention to submit BLA to US FDA in 2017
  • 01 Dec 2015 Phase-III clinical trials in Immunodeficiency disorders (In adults, In children, Treatment-experienced) in USA (IV-infusion) (NCT02269163)
  • 26 Oct 2015 The US FDA approves IND application for Intravenous immunoglobulin in Immunodeficiency disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top